144 related articles for article (PubMed ID: 37725810)
1. Carbapenem-resistant Klebsiella pneumoniae Osteoarthritis in Two Preterm Infants Treated With Ceftazidime-avibactam.
Pu W; Fan L; Zhang Y; You D; Li M; Ma L
Pediatr Infect Dis J; 2023 Dec; 42(12):1124-1127. PubMed ID: 37725810
[TBL] [Abstract][Full Text] [Related]
2. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Karampatakis T; Tsergouli K; Lowrie K
Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964
[TBL] [Abstract][Full Text] [Related]
4. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
[TBL] [Abstract][Full Text] [Related]
6. Increased Expression and Amplification of
Li X; Zhang J; Yang C; Li J; Wang J; Huang W; Zeng L; Liang X; Long W; Zhang X
Microbiol Spectr; 2022 Aug; 10(4):e0095522. PubMed ID: 35900090
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P
Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802
[TBL] [Abstract][Full Text] [Related]
8. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
9. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae.
Lima O; Sousa A; Longueira-Suárez R; Filgueira A; Taboada-Martínez C; Portela-Pino C; Nodar A; Vasallo-Vidal F; Martinez-Lamas L; Pérez-Landeiro A; Rubianes M; Pérez-Rodríguez MT
Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1173-1182. PubMed ID: 35939239
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P
Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353
[TBL] [Abstract][Full Text] [Related]
12. A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
Luterbach CL; Qiu H; Hanafin PO; Sharma R; Piscitelli J; Lin FC; Ilomaki J; Cober E; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Nation RL; Bonomo RA; Landersdorfer CB; van Duin D; Rao GG;
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0059122. PubMed ID: 36125299
[TBL] [Abstract][Full Text] [Related]
13. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.
Liao Q; Deng J; Feng Y; Zhang W; Wu S; Liu Y; Che H; Xie Y
J Infect Public Health; 2022 May; 15(5):545-549. PubMed ID: 35461077
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant
Ahmed F; Abraham B; Kamal Saeed N; Mohamed Naser H; Sridharan K
Crit Care Res Pract; 2024; 2024():3427972. PubMed ID: 38868174
[TBL] [Abstract][Full Text] [Related]
15. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of a Stable and Transferable
Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
[TBL] [Abstract][Full Text] [Related]
17. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella
Guo Y; Liu N; Lin Z; Ba X; Zhuo C; Li F; Wang J; Li Y; Yao L; Liu B; Xiao S; Jiang Y; Zhuo C
Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677
[TBL] [Abstract][Full Text] [Related]
18. Off-Label Use of Ceftazidime-Avibactam in a Premature Infant With Multidrug-Resistant
Nascimento ADS; Passaro MF; Silva PSS; Rodriguez SF; Martins MK; Oliveira SCP; Moriel P; Visacri MB
J Pharm Pract; 2023 Aug; 36(4):1020-1025. PubMed ID: 35414301
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
